相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial
W. Schrempf et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease
Eva Szoeko et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects
Peter Riederer et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
90years of monoamine oxidase: some progress and some confusion
Keith F. Tipton
JOURNAL OF NEURAL TRANSMISSION (2018)
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Anthony E. Lang et al.
MOVEMENT DISORDERS (2018)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study
Miho Murata et al.
NEUROLOGY (2018)
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease
Joaquim J. Ferreira et al.
NEUROLOGY (2018)
Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease
Chin-Hsien Lin et al.
PARKINSONISM & RELATED DISORDERS (2018)
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review
Irene Katsaiti et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Opicapone for the treatment of Parkinson's disease
Filipe B. Rodrigues et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Emanuele Cereda et al.
JOURNAL OF NEUROLOGY (2017)
Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia
Laura L. Frakey et al.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES (2017)
A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson's Disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2017)
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease
Thomas Mueller et al.
CLINICAL NEUROPHARMACOLOGY (2017)
Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis
Ying Chang et al.
ANNALS OF MEDICINE (2017)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
Joaquim J. Ferreira et al.
LANCET NEUROLOGY (2016)
Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)
J. Knoll et al.
LIFE SCIENCES (2016)
Long-term effects of rasagiline and the natural history of treated Parkinson's disease
Olivier Rascol et al.
MOVEMENT DISORDERS (2016)
Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis
Nir Giladi et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
John P. M. Finberg et al.
FRONTIERS IN PHARMACOLOGY (2016)
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease
Jose-Francisco Rocha et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Behavioral Effects of β-Phenylethylamine and Various Monomethylated and Monohalogenated Analogs in Mice Are Mediated by Catecholaminergic Mechanisms
Aron D. Mosnaim et al.
AMERICAN JOURNAL OF THERAPEUTICS (2015)
Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease
Thomas Mueller
DRUGS (2015)
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease
J. J. Ferreira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off
Mikko Kuoppamaki et al.
JOURNAL OF NEURAL TRANSMISSION (2015)
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
Jasmin Bartl et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
Joseph Jankovic et al.
PARKINSONISM & RELATED DISORDERS (2014)
Striatal Astrocytes Act as a Reservoir for L-DOPA
Masato Asanuma et al.
PLOS ONE (2014)
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders
David S. Goldstein et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release
John P. M. Finberg
PHARMACOLOGY & THERAPEUTICS (2014)
Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects
Jose Francisco Rocha et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation
O. Sader-Mazbar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Monoamine Oxidase Inhibitors Revisited: What You Should Know
Joseph F. Goldberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease
Thomas Mueller et al.
JOURNAL OF NEURAL TRANSMISSION (2013)
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease
David S. Goldstein et al.
JOURNAL OF NEUROCHEMISTRY (2013)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway
Yuval Aluf et al.
NEUROPHARMACOLOGY (2013)
Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
Geraldine H. Petit et al.
PLOS ONE (2013)
Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
M. A. Cenci et al.
CNS & Neurological Disorders-Drug Targets (2012)
Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase
Orit Bar-Am et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
A Randomized, Double-Blind, Placebo-Controlled Trial of Safinamide as Add-on Therapy in Early Parkinson's Disease Patients
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2012)
RASAGILINE INTERFERES WITH NEURODEGENERATION IN THE PRPH2/RDS MOUSE
Sylvie Eigeldinger-Berthou et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2012)
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease
F. Stocchi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Advances Pertaining to the Pharmacology and Interactions of Irreversible Nonselective Monoamine Oxidase Inhibitors
Peter Kenneth Gillman
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Rasagiline-induced Delay of Retinal Ganglion Cell Death in Experimental Glaucoma in Rats
Hani Levkovitch-Verbin et al.
JOURNAL OF GLAUCOMA (2011)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Olivier Rascol et al.
LANCET NEUROLOGY (2011)
Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
Peter Jenner et al.
MOVEMENT DISORDERS (2011)
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease
Sylvia Navailles et al.
NEUROBIOLOGY OF DISEASE (2011)
Alterations in striatal oxidative stress level produced by pharmacological manipulation of dopamine as shown by a novel synthetic marker molecule
Y. Aluf et al.
NEUROPHARMACOLOGY (2011)
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
David Brooks
Neuropsychiatric Disease and Treatment (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevance
Patricia K. Sonsalla et al.
EXPERIMENTAL NEUROLOGY (2010)
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline
Tamar Goren et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
Orit Bar-Am et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease
Sylvia Navailles et al.
NEUROBIOLOGY OF DISEASE (2010)
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)
Paolo Solla
Neuropsychiatric Disease and Treatment (2010)
Molecular and Mechanistic Properties of the Membrane-Bound Mitochondrial Monoamine Oxidases
Dale E. Edmondson et al.
BIOCHEMISTRY (2009)
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily
Mikko Kuoppamaki et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Unfaithful neurotransmitter transporters: Focus on serotonin uptake and implications for antidepressant efficacy
Lynette C. Daws
PHARMACOLOGY & THERAPEUTICS (2009)
Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in Post-MPTP-induced parkinsonism via activation of tyrosine kinase receptor signaling pathway
Silvia A. Mandel et al.
NEUROCHEMICAL RESEARCH (2007)
Tolcapone improves cognition and cortical information processing in normal human subjects
Jose A. Apud et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Selegiline and blood pressure in patients with Parkinson's disease
V. Pursiainen et al.
ACTA NEUROLOGICA SCANDINAVICA (2007)
Zonisamide improves motor function in Parkinson disease - A randomized, double-blind study
Miho Murata et al.
NEUROLOGY (2007)
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
Jack J. Chen et al.
CLINICAL THERAPEUTICS (2007)
TCH346 as a neuroprotective drug in Parkinsons disease: a double-blind, randomised, controlled trial
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Safinamide - From molecular targets to a new anti-Parkinson drug
C. Caccia et al.
NEUROLOGY (2006)
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease
C. Warren Olanow
NEUROLOGY (2006)
The therapeutic potential of monoamine oxidase inhibitors
MBH Youdim et al.
NATURE REVIEWS NEUROSCIENCE (2006)
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
J. Antonelle deMarcaida et al.
MOVEMENT DISORDERS (2006)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates
LA Smith et al.
MOVEMENT DISORDERS (2005)
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats
C Marin et al.
EXPERIMENTAL NEUROLOGY (2005)
Genetic basis for individual variations in pain perception and the development of a chronic pain condition
L Diatchenko et al.
HUMAN MOLECULAR GENETICS (2005)
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
O Bar Am et al.
NEUROSCIENCE LETTERS (2004)
Catecholamine metabolism: A contemporary view with implications for physiology and medicine
G Eisenhofer et al.
PHARMACOLOGICAL REVIEWS (2004)
Entacapone increases and prolongs the central effects of L-DOPA in the 6-hydroxydopamine-lesioned rat
M Gerlach et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline:: A potent, selective, and irreversible monoamine oxidase type B inhibitor
JJ Thébault et al.
PHARMACOTHERAPY (2004)
Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens
S Glezer et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension
KF Bhattacharya et al.
PARKINSONISM & RELATED DISORDERS (2003)
Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease
M Asanuma et al.
NEUROTOXICITY RESEARCH (2003)
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours
JPM Finberg et al.
NEUROPHARMACOLOGY (2002)
Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP
J Knoll et al.
LIFE SCIENCES (2002)
Neuroprotection by propargylamines in Parkinson's disease - Suppression of apoptosis and induction of prosurvival genes
W Maruyama et al.
NEUROTOXICOLOGY AND TERATOLOGY (2002)
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
I Shoulson et al.
ANNALS OF NEUROLOGY (2002)
Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines
O Yanagida et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2001)
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol
W Maruyama et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
MBH Youdim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Adverse drug reactions to selegiline: A review of the French Pharmacovigilance Database
JL Montastruc et al.
CLINICAL NEUROPHARMACOLOGY (2000)
分享论文
